1. Home
  2. BUUU vs HURA Comparison

BUUU vs HURA Comparison

Compare BUUU & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BUUU

BUUU Group Limited Class A Ordinary Share

N/A

Current Price

$7.89

Market Cap

129.6M

ML Signal

N/A

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$0.69

Market Cap

131.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUUU
HURA
Founded
2017
2009
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
129.6M
131.8M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
BUUU
HURA
Price
$7.89
$0.69
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
107.4K
351.6K
Earning Date
02-20-2026
02-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$6,328,425.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$149.17
N/A
Revenue Growth
8.88
N/A
52 Week Low
$3.67
$0.68
52 Week High
$20.76
$5.27

Technical Indicators

Market Signals
Indicator
BUUU
HURA
Relative Strength Index (RSI) N/A 28.40
Support Level N/A $0.70
Resistance Level N/A $0.78
Average True Range (ATR) 0.00 0.06
MACD 0.00 0.04
Stochastic Oscillator 0.00 0.42

Price Performance

Historical Comparison
BUUU
HURA

About BUUU BUUU Group Limited Class A Ordinary Share

BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: